Saadoun D, Bodaghi B, Cacoub P (2024) Behçet’s syndrome. N Engl J Med 390:640–651. https://doi.org/10.1056/NEJMRA2305712

Article  CAS  PubMed  Google Scholar 

Emmi G, Bettiol A, Hatemi G, Prisco D (2024) Behçet’s syndrome. Lancet (London England) 403:1093–1108. https://doi.org/10.1016/S0140-6736(23)02629-6

Article  CAS  PubMed  Google Scholar 

Hatemi G, Christensen R, Bang D et al (2018) 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis 77:808–818. https://doi.org/10.1136/ANNRHEUMDIS-2018-213225

Article  PubMed  Google Scholar 

Ozguler Y, Leccese P, Christensen R et al (2018) Management of major organ involvement of Behçet’s syndrome: a systematic review for update of the EULAR recommendations. Rheumatology (Oxford) 57:2200–2212. https://doi.org/10.1093/RHEUMATOLOGY/KEY242

Article  PubMed  Google Scholar 

Leccese P, Ozguler Y, Christensen R et al (2019) Management of skin, mucosa and joint involvement of Behçet’s syndrome: a systematic review for update of the EULAR recommendations for the management of Behçet’s syndrome. Semin Arthritis Rheum 48:752–762. https://doi.org/10.1016/J.SEMARTHRIT.2018.05.008

Article  PubMed  Google Scholar 

Sfikakis PP, Theodossiadis PG, Katsiari CG et al (2001) Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358:295–296. https://doi.org/10.1016/S0140-6736(01)05497-6

Article  CAS  PubMed  Google Scholar 

Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti-TNF therapy in the management of Behçet’s disease—review and basis for recommendations. Rheumatology 46:736–741. https://doi.org/10.1093/RHEUMATOLOGY/KEM034

Article  CAS  PubMed  Google Scholar 

Ohno S, Umebayashi I, Matsukawa M et al (2019) Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet’s disease: a large-scale, long-term postmarketing surveillance in Japan. Arthritis Res Ther 21:1–12. https://doi.org/10.1186/S13075-018-1793-7/TABLES/5

Article  Google Scholar 

Hatemi G, Tukek NB, Esatoglu SN et al (2023) Infliximab for vascular involvement in Behçet’s syndrome. Clin Immunol 253. https://doi.org/10.1016/J.CLIM.2023.109682

Evangelatos G, Bamias G, Kitas GD et al (2022) The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era. Rheumatol Int 42:1493–1511. https://doi.org/10.1007/S00296-022-05136-X

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sfikakis PP, Arida A, Panopoulos S et al (2017) Brief report: drug-free long-term remission in severe Behçet’s Disease following withdrawal of successful anti–tumor necrosis factor treatment. Arthritis Rheumatol 69:2380–2385. https://doi.org/10.1002/art.40235

Article  CAS  PubMed  Google Scholar 

International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335:1078–1080. https://doi.org/10.1016/0140-6736(90)92643-V

Article  Google Scholar 

Lawton G, Bhakta BB, Chamberlain MA, Tennant A (2004) The Behcet’s disease activity index. Rheumatology (Oxford) 43:73–78. https://doi.org/10.1093/RHEUMATOLOGY/KEG453

Article  CAS  PubMed  Google Scholar 

Köse HC, Yalçındağ N (2022) Clinical follow-up of patients with Behçet Uveitis after Discontinuation of Infliximab Therapy. Ocul Immunol Inflamm 30:203–207. https://doi.org/10.1080/09273948.2020.1774907

Article  CAS  PubMed  Google Scholar 

Reenaers C, Mary JY, Nachury M et al (2018) Outcomes 7 years after Infliximab Withdrawal for patients with Crohn’s Disease in Sustained Remission. Clin Gastroenterol Hepatol 16:234–243e2. https://doi.org/10.1016/J.CGH.2017.09.061

Article  PubMed  Google Scholar 

Talarico R, Italiano N, Emmi G et al (2024) Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet’s syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial. Ann Rheum Dis. https://doi.org/10.1136/ARD-2024-226113

Article  PubMed  Google Scholar 

Zhong Z, Deng D, Gao Y et al (2024) Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Behçet’s disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial. https://doi.org/10.1016/S2665-9913(24)00194-2. Lancet Rheumatol 6:

Moots RJ, Fortune F, Jackson R et al (2024) Infliximab versus interferon-alpha in the treatment of Behçet’s syndrome: clinical data from the BIO-BEHÇET’S randomised controlled trial. Rheumatology (Oxford). https://doi.org/10.1093/RHEUMATOLOGY/KEAE585

Article  PubMed  Google Scholar 

Saadoun D, Maalouf G, Vieira M et al (2024) Infliximab versus Cyclophosphamide for severe Behçet’s syndrome. NEJM Evid 3. https://doi.org/10.1056/EVIDOA2300354

Guzelant G, Ucar D, Esatoglu SN et al (2017) Infliximab for uveitis of Behçet’s syndrome: a trend for earlier initiation. Clin Exp Rheumatol 35:S86–S89

Google Scholar 

Sota J, Rigante D, Lopalco G et al (2018) Biological therapies for the treatment of Behçet’s disease-related uveitis beyond TNF-alpha blockade: a narrative review. Rheumatol Int 38:25–35. https://doi.org/10.1007/S00296-017-3775-5

Article  CAS  PubMed  Google Scholar 

Tukek NB, Esatoglu SN, Hatemi G et al (2022) Emergence of new manifestations during infliximab treatment in Behçet’s syndrome. Rheumatology (Oxford) 61:3746–3753. https://doi.org/10.1093/RHEUMATOLOGY/KEAB944

Article  CAS  PubMed  Google Scholar 

Esatoglu SN, Sonmez O, Ucar D et al (2024) De novo manifestations during adalimumab treatment in Behçet’s syndrome. Rheumatology (Oxford). https://doi.org/10.1093/RHEUMATOLOGY/KEAE416

Article  PubMed  Google Scholar 

Fragoulis GE, Bertsias G, Bodaghi B et al (2023) Treat to target in Behcet’s disease: should we follow the paradigm of other systemic rheumatic diseases? Clin Immunol 246. https://doi.org/10.1016/J.CLIM.2022.109186